DMD treatment SMT-01, a cell replacement therapy, received FDA orphan drug and rare pediatric disease designations.

Columnist Betty Vertin is going gray — as in, she's decided to stop coloring her hair. Did DMD play a role in this decision, she wonders.

For a long time, columnist Robin Stemple resisted using a walker to navigate around his home, but eventually, he had to put ...

Losmapimod, an investigational medication from Fulcrum Therapeutics, failed to significantly outperform a placebo at ...

Last Saturday, I had the honor of participating in the third Singapore Health Patient Advocate Connection event (SPACe) ...

Atamyo has partnered with the Dion Foundation to expand into the U.S. a clinical trial testing the gene therapy ATA-200 for ...

SMT-M01, a Duchenne muscular dystrophy (DMD) treatment, was granted orphan drug and rare pediatric disease designations by the U.S. Food and Drug Administration (FDA). The cell replacement therapy ...

The U.S. Food and Drug Administration granted rare pediatric disease designation to NS-050/NCNP-03, an exon-skipping DMD ...

Columnist Shalom Lim reflects on how he and his late brother, Isaac, left their mark on the Singaporean DMD community as ...

For columnist Patrick Moeschen, a teacher and wheelchair user, each school year is an opportunity for teaching students about ...